NONDISCRIMINATION AND CONFIDENTIALITY STATEMENT 

As a participant of the MCI Leukemia Case Review Series involved in the evaluation and improvement of quality of care and service, I recognize that confidentiality is vital. Therefore, I agree to respect and maintain the confidentiality of all discussions, records and information generated in connection within the MCI Leukemia Case Review Series and to make no voluntary disclosure of such information except to persons authorized. As a participant of the MCI Leukemia Case Review Series, I will ensure that my participation in the peer review process and discussions will be made in a non-discriminatory manner and will not be made based on the patients' race, ethnic/national identity, gender, age, sexual orientation, or patient population for which they serve.

DISCLOSURE STATEMENT 

Firas El Chaer, M.D., moderator of this educational activity, receives grant and research support from Amgen, Celgene, SPD Oncology, Sanofi, Bristol Myers Squibb, FibroGen, PharmaEssentia, BioSight, MEI Pharma, Novartis and Arog Pharm. The moderator is also a consultant for SPD Oncology, Amgen, CTI BioPharma, AbbVie, MorphoSys, PharmaEssentia, Bristol Myers Squibb, Geron and Sobi. 

All of the relevant financial relationships listed for this individual have been mitigated.

*Ineligible Companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.